Blood cancers

Pay attention to early response in multiple myeloma

Response after just two cycles of a bortezomib-based induction therapy appears to predict depth of response at the end of induction and subsequent survival in patients with multiple myeloma. The findings, from a review of patients treated between 2009 and 2016 at Monash Health, suggest non-responders can be identified early and may require an escalation ...

Already a member?

Login to keep reading.

© 2021 the limbic